Luminex Corporation Settles Legal Dispute

AUSTIN, Texas--(Business Wire)--
Luminex Corporation (NASDAQ:LMNX) today announced that it has settled the
pending litigation with The Research Foundation for the State University of New
York and the Board of Trustees of the University of Illinois ("Plaintiffs"). As
part of the settlement, the Plaintiffs received a one time cash payment of $4.35
million with no admission of fault. The cash payment was made by Luminex in
exchange for resolution of the dispute between the parties and a complete
release of all claims by the Plaintiffs against Luminex, and, correspondingly a
complete release of all claims by Luminex against the Plaintiffs. The entire
effect of the settlement payment will be reflected as a non-recurring item in
the first quarter financial results scheduled to be released on May 7, 2009. All
other terms of the agreement are confidential. The parties intend to formally
dismiss the lawsuit, as required by the Settlement Agreement.

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary biological
testing technologies with applications throughout the diagnostic and life
sciences industries. The Company's xMAP multiplex solutions include an
open-architecture, multi-analyte technology platform that delivers fast,
accurate and cost-effective bioassay results to markets as diverse as
pharmaceutical drug discovery, clinical diagnostics and biomedical research,
including the genomics and proteomics research markets. The Company's xMAP
technology is sold worldwide and is already in use in leading clinical
laboratories as well as major pharmaceutical, diagnostic and biotechnology
companies. Further information on Luminex Corporation or xMAP technology can be
obtained at www.luminexcorp.com.

Statements made in this release that express Luminex's or management's
intentions, plans, beliefs, expectations or predictions of future events are
forward-looking statements. The words "believe," "expect," "intend," "estimate,"
"anticipate," "will," "could," "should" and similar expressions are intended to
further identify such forward-looking statements for purposes of the Private
Securities Litigation Reform Act of 1995.It is important to note that the
Company's actual results or performance could differ materially from those
anticipated or projected in such forward-looking statements.Factors that could
cause Luminex's actual results or performance to differ materially include risks
and uncertainties relating to, among others, market demand and acceptance of
Luminex's products, the Company's dependence on strategic partners for
development, commercialization and distribution of products, concentration of
the Company's revenue in a limited number of strategic partners, fluctuations in
quarterly results due to a lengthy and unpredictable sales cycle and bulk
purchases of consumables, Luminex's ability to scale manufacturing operations
and manage operating expenses, gross margins and inventory levels, potential
shortages of components, competition, the timing of regulatory approvals, the
implementation, including any modification, of the Company's strategic operating
plans, risks and uncertainties associated with implementing our acquisition
strategy and the ability to integrate acquired companies or selected assets into
our consolidated business operations, as well as the risks discussed under the
heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed
with the Securities and Exchange Commission.The forward-looking statements
contained herein represent the judgment of Luminex as of the date of this press
release, and Luminex expressly disclaims any intent, obligation or undertaking
to release publicly any updates or revisions to any forward-looking statements
to reflect any change in Luminex's expectations with regard thereto or any
change in events, conditions or circumstances on which any such statements are
based.

Luminex Corporate Contact:
Harriss T. Currie, 512-219-8020
Vice President, Finance and Chief Financial Officer
hcurrie@luminexcorp.com
or
Luminex Investor Relations Contact:
Mimi Torrrington, 512-219-8020
Director of Investor Relations
mtorrington@luminexcorp.com

Copyright Business Wire 2009